Cristina Fernández-Canal

  • Citations Per Year
Learn More
Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when treatment is withdrawn but the frequency of this phenomenon is unknown. We retrospectively evaluated 260 adult primary ITP patients (165 women and 95 men; median age, 62 years) treated with eltrombopag after a median time from diagnosis(More)
Methods This prospective, interventional study was approved by the appropriate Institutional Review Board (Comité de Protection des Personnes Sud-Est VI, Clermont-Ferrand, France; NCT02202720) and conducted in a 16-bed ICU. For each patient, the sevoflurane MAC were increased to 0.1 MAC every 30 minutes from MAC 0 until MAC 0.8 then reduced with the same(More)
  • 1